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Abstract
Background: Left ventricular (LV) remodeling following acute myocardial infarction (MI) is difficult to predict at an
individual level although a possible interfering role of vascular function has yet to be considered to date. This study
aimed to determine the extent to which this LV remodeling is influenced by the concomitant evolution of vascular
function and LV loading conditions, as assessed by phase-contrast Cardiovascular Magnetic Resonance (CMR) of the
ascending aorta.
Methods: CMR was performed in 121 patients, 2–4 days after reperfusion of a first ST-segment elevation myocardial
infarction and 6 months thereafter. LV remodeling was: (i) assessed by the 6-month increase in end-diastolic volume
(EDV) and/or ejection fraction (EF) and (ii) correlated with the indexed aortic stroke volume (mL.m−2), determined by a
CMR phase-contrast sequence, along with derived functional vascular parameters (total peripheral vascular resistance
(TPVR), total arterial compliance index, effective arterial elastance).
Results: At 6 months, most patients were under angiotensin enzyme converting inhibitors (86%) and beta-blockers
(84%) and, on average, all functional vascular parameters were improved whereas blood pressure levels were not. An
increase in EDV only (EDV+/EF-) was documented in 17% of patients at 6 months, in EF only (EDV-/EF+) in 31%,
in both EDV and EF (EDV+/EF+) in 12% and neither EDV nor EF (EDV-/EF-) in 40%. The increase in EF was mainly
and independently linked to a concomitant decline in TPVR (6-month change in mmHg.min.m2.L−1, EDV-/EF-: +1 ± 8,
EDV+/EF-: +3 ± 9, EDV-/EF+: -7 ± 6, EDV+/EF+: -15 ± 20, p < 0.001) while the absence of any EF improvement was
associated with high persisting rates of abnormally high TPVR at 6 months (EDV-/EF-: 31%, EDV+/EF-: 38%, EDV-/EF+:
5%, EDV+/EF+: 13%, p = 0.007). By contrast, the 6–month increase in EDV was mainly dependent on cardiac as
opposed to vascular parameters and particularly on the presence of microvascular obstruction at baseline (EDV-/EF-:
37%, EDV+/EF-: 76%, EDV-/EF+: 38%, EDV+/EF+: 73%, p = 0.003).
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Conclusion: LV remodeling following reperfused MI is strongly influenced by the variable decrease in systemic vascular
resistance under standard care vasodilating medication. The CMR monitoring of vascular resistance may help to tailor
these medications for improving vascular resistance and consequently, LV ejection fraction.
Trial registration: NCT01109225 on ClinicalTrials.gov site (April, 2010).
Keywords: Hemodynamics, Myocardial infarction, Cardiac remodeling, Peripheral vascular resistance, Cardiovascular
magnetic resonance, CMR
Background
Left ventricular (LV) remodeling following acute myocar-
dial infarction (MI) is a complex process possibly leading
in the first months to an improvement in ejection fraction
(reverse remodeling [1–3]) and to an increased end-
diastolic volume (adverse remodeling [1, 4, 5]). This re-
modeling is difficult to predict at an individual level al-
though a possible interfering role of vascular function
has never been considered to date.
Cardiovascular Magnetic resonance (CMR) has gained
a pivotal role in assessing LV function and for character-
izing MI areas in this setting [4, 6]. Aortic stroke volume
(SV), along with derived functional vascular parameters,
can also be assessed with phase-contrast CMR, inde-
pendently of LV volume values and with an accuracy
level that is not reached by Doppler techniques [7].
The combined analysis of brachial blood pressure (BP)
and of the SV producing the BP wave has been recently
shown to significantly improve the CMR characterization
of LV remodeling in hypertensive patients [8, 9]. This im-
provement is notably due to the precise information ob-
tained on LV loading conditions with the non-invasive
determination of various parameters such as total periph-
eral vascular resistance, total arterial compliance index
and effective arterial elastance [8–13]. However, this vas-
cular monitoring has yet to be investigated in the context
of LV remodeling following reperfused acute MI and
where patients are commonly referred to hypotensive
medical regimens (angiotensin converting enzyme (ACE)
inhibitors, beta-blockers). These medications are indeed
likely to influence blood pressure and vascular function
and thereby, LV wall stress, a main stimulus for adverse
LV remodeling [1].
In light of the above, the present study was aimed at
determining the extent to which vascular function and
LV loading conditions, assessed through an aortic phase-
contrast CMR sequence, and their changes over time in-
fluences LV remodeling following reperfused MI.
Methods
Study population
The study population was extracted from the single-
center “REMI” (relation between aldosterone and cardiac
REmodeling after Myocardial Infarction) cohort in which
serial CMR and biomarker measurements were performed
after reperfused acute MI [14, 15]. The study protocol, in
compliance with the Declaration of Helsinki, was approved
by the local Ethics Committee (CPP agreement n° 2009-
A00537-50) and was registered on the ClinicalTrials.gov
site (NCT01109225). All subjects gave signed informed
consent to participate.
Patients successfully treated by primary percutaneous
transluminal coronary angioplasty for a first ST-segment
elevation myocardial infarction (STEMI) were prospect-
ively included. In order to be retained, acute STEMI had
to be associated with a significant rise in cardiac enzymes
and with an initial occlusion or sub-occlusion of the
MI-related artery at angiography (Thrombolysis In
Myocardial Infarction flow grade 0 to 1). Main exclusion
criteria were: (i) previous history of MI, (ii) any other sig-
nificant cardiac disease (including > grade-2 mitral regur-
gitation), (ii) any contraindication to CMR, (iii) absence of
sinus cardiac rhythm, (iv) a multivessel disease at coronary
angiography and (v) a >12 h delay-time between the onset
of chest pain and reperfusion. The patients were referred
to a medical check-up involving CMR at 2 to 4 days after
acute MI reperfusion and 6 months (±15 days) later.
CMR
CMR was performed on a single 3 T magnet (Signal
HDxt, GE Healthcare, Milwaukee, Wisconsin) equipped
with a dedicated cardiac coil. Systolic, diastolic and mean
brachial blood pressures (BP) were measured with an au-
tomated sphygmomanometer (Maglife C, Schiller Medical,
Wissembourg, France). Three measurements were ob-
tained during the CMR examination and mean values
were stored for analyses herein.
A steady-state free precession pulse sequence was used
to assess LV function in contiguous short axis planes.
Each plane was recorded as previously detailed [8, 9, 16],
and LV end-diastolic volume (EDV), end-systolic volume
and ejection fraction (EF) were obtained by an expert
cardiologist, using dedicated software (MASS research
v2013-exp™, Medis, Leiden University Medical Center,
The Netherlands). Main acquisition parameters were as
follows: 8 mm slice-thickness, 3.5–3.9 ms repetition time,
14 to 16 K-space lines per segment, 1.5 ASSET factor, 30
phases per cardiac cycle with view sharing, field-of-view
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(FOV) ranging from 32 to 38 cm with a phase FOV of 0.9,
and a 224x224 matrix interpolated to 256x256.
Flow was determined in the ascending aorta using a
velocity-encoded phase-contrast gradient-echo sequence
and with the “CV flow” software (Leiden University
Medical Center, Medis, The Netherlands) [8, 9]. Velocities
were corrected by a ROI-based method only in instances
of evident offset error [7]. Acquisition parameters were as
follows: 8 mm slice-thickness, 10° flip angle, 3–4 ms echo
time, 6–7 ms repetition time, 31 kHz bandwidth, 6 K-space
lines per segment, 32 phases per cardiac cycle with view
sharing, unidirectional velocity encoding with a maximal
velocity set to 150 cm.sec−1, FOV between 30 to 38 cm
with a phase FOV of 0.85, and a 256x128 matrix interpo-
lated to 256x256. Aortic stroke volume (SV) was indexed
to body surface area and used to calculate the following
[8, 9]: cardiac index (SV x heart rate), total arterial
compliance index (TAC: SV/pulse pressure), effective
arterial elastance (Ea: mean BP/SV), stroke work (mean
BP x SV) and total peripheral vascular resistance (TPVR: mean
BP/cardiac index). TPVR values above 40 mmHg.min.m2.L−1
were considered as abnormally high, a threshold corre-
sponding to the upper limit of the 95% confidence
interval in an already-described normal population of
100 subjects with comparable age range and CMR
protocol as in the population of subjects in the current
study [9].
The MI area was analyzed on 8 to 10 short axis slices
covering the LV volume and two vertical and horizontal
long-axis slices, which were recorded with a T1-weighted
segmented phase-sensitive inversion-recovery (PSIR) se-
quence 10 to 15 min after the injection of a gadolinium-
labeled tracer (0.1 mmol.kg−1 of body weight of Dotarem®,
GUERBET, France) with the following parameters:
4.7/2.1 msec for TR/TE, a typical 250–350 msec in-
version time adjusted to null the signal of the non-in-
farcted myocardium, 28–35 cm field-of-view, 192x128
matrix interpolated to 256x256, 8 mm slice-thickness and
20° flip angle.
The MI volume was considered as that showing a late
gadolinium enhancement (LGE) by visual analysis and
expressed in % of the total LV volume by using a 17-
segment LV division and while taking into account the
number of quartiles involved in each segment [16, 17].
The size of the transmural MI was determined as the %
of LV segments showing a LGE ≥75% of myocardial
thickness, while its involvement in microvascular obstruc-
tion was determined as that showing a central hypo en-
hancement within the bright signal [4].
Table 1 Main general characteristics of the study population at
baseline (n = 121)
Age (years) 56 ± 10
Female gender 18 (15%)
Hypertension 39 (32%)
Diabetes Mellitus 10 (8%)
Hypercholesterolemia 47 (39%)
Obesity 9 (7%)
Peak Troponin-Ic (ng/ml) 922 ± 2014
Primary angioplasty
Use of glycoprotein IIb/IIIa inhibitor 77 (64%)
Delay from pain onset (hours) 4.3 ± 2.3
MI-related coronary artery
- left anterior descending artery 65 (54%)
- right coronary artery 45 (37%)
- left circumflex artery 11 (9%)
Stent implantation 117 (97%)
Table 2 Main parameters recorded at baseline and at 6 months
with p values for significant paired comparisons
Baseline 6 months p-value
Main medications
- Beta-blockers 100 (83%) 101 (84%)
- ACE inhibitors 103 (85%) 104 (86%)
- Statins 110 (91%) 105 (87%)
- Antiplatelet therapy 120 (99%) 115 (95%)
Body mass index (kg.m−2) 25 ± 4 25 ± 4
Heart rate (bpm) 66 ± 11 57 ± 8 < 0.001
BP parameters
Systolic BP (mmHg) 129 ± 21 130 ± 20
Diastolic BP (mmHg) 75 ± 14 72 ± 11
Mean BP (mmHg) 93 ± 15 92 ± 13
Cardiac parameters
LV end-diastolic volume (mL.m−2) 92 ± 15 96 ± 18 0.006
LV ejection fraction (%) 42 ± 8 49 ± 9 < 0.001
Total MI area (% of LV) 22 ± 12 16 ± 11 < 0.001
Transmural MI - presence (%) 94 (78%) 55 (46%) < 0.001
- area (% of LV) 16 ± 13 8 ± 11 < 0.001
MVO - presence (%) 59 (49%) 0 (0%) < 0.001
- area (% of LV) 8 ± 11 0 ± 0 < 0.001
SV-derived parameters
SV (mL.m−2) 38 ± 8 47 ± 9 < 0.001
Cardiac index (L.min−1.m−2) 2.4 ± 0.4 2.6 ± 0.5 < 0.001
TPVR (mmHg.min.m2.L−1) 39 ± 11 36 ± 9 0.001
TAC (mL.m−2.mmHg−1) 0.74 ± 0.21 0.83 ± 0.22 < 0.001
Ea (mmHg.m2.mL−1) 2.6 ± 0.9 2.1 ± 0.6 < 0.001
Stroke Work (L.mmHg.m−2) 3.5 ± 0.9 4.3 ± 1.0 < 0.001
ACE angiotensin converting enzyme, BP blood pressure, Ea effective arterial
elastance, LV left ventricular, MI myocardial infarction, MVO microvascular
obstruction, SV stroke volume, TAC total arterial compliance, TPVR total
peripheral vascular resistance
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Intra-observer reproducibility of the determinations of
LV-volumes and EF was assessed in 30 consecutive CMR
exams from the present cohort which were analyzed
twice in an interval greater than 1 month apart. Absolute
values of the relative variations between the first and sec-
ond measurements were on average 6.59 ± 5.33 mL for
EDV and 2.95 ± 2.65% for EF.
Statistical analysis
LV remodeling was assessed by the increases in EDV and
EF between baseline and 6 months, and the corresponding
thresholds were determined as the upper limits of the 95%
confidence interval of the reproducibility analysis described
above, i.e. >17.3 mL for EDV and >8.3% for EF.
Continuous variables are expressed as means ± standard de-
viation [SD] and discrete variables as percentages. Paired
comparisons between baseline and 6 months were performed
with Wilcoxon tests for continuous variables and McNemar
tests for percentages. Unpaired comparisons of continuous
variables were performed with Mann-Whitney tests when
comparing two groups and with Kruskal-Wallis tests for
more than 2 groups. Unpaired intergroup comparisons of
discrete variables were performed with chi-square tests or
Fisher's exact tests where appropriate. Significant univariate
predictors of an increase in EDV or in EF at 6 months were
investigated among the baseline variables listed in Tables 1
and 2 as well as among the 6-month changes in vascular pa-
rameters (BP, TPVR, TAC and Ea). In all above tests, a 2-
sided p-value < 0.05 was considered statistically significant.
Multivariable stepwise logistic regressions were also
applied for predicting an increase in EDV or in EF at
6 months, with backward-forward selection among signifi-
cant univariate predictors and with p-values of 0.05 and
0.10 for entering and removing the variables, respectively.
Results
Patient characteristics at baseline
A total of 141 patients were included, among whom 20 had
no CMR at 6 months (three with contraindications and 17
consent withdrawals), yielding a total of 121 patients for the
Table 3 Mean (± SD) and p values for the significant univariate correlates of the two-group comparisons between patients with and
those without 6-month increases in LV end-diastolic volume (EDV, left panel) or in ejection fraction (EF, right panel)











Delay from pain onset (hours) 4.9 ± 2.9 4.0 ± 1.9 NS 4.4 ± 2.3 4.1 ± 2.3 NS
MI-related coronary artery
- left anterior descending artery 24 (67%) 41 (48%) NS 29 (56%) 36 (52%) NS
- right coronary artery 10 (28%) 35 (41%) NS 20 (38%) 25 (36%) NS
- left circumflex artery 2 (6%) 9 (11%) NS 3 (6%) 8 (12%) NS
Heart rate (bpm) 69 ± 12 64 ± 10 0.037 67 ± 12 65 ± 9 NS
LV ejection fraction (%) 40 ± 8 43 ± 8 0.041 39 ± 8 44 ± 7 <0.001
Total MI area (% of LV) 25 ± 12 20 ± 11 0.022 22 ± 12 22 ± 11 NS
Transmural MI area (% of LV) 21 ± 13 14 ± 12 0.007 16 ± 12 16 ± 13 NS
MVO - presence (%) 27 (75%) 32 (38%) <0.001 25 (48%) 34 (49%) NS
- area (% of LV) 13 ± 12 6 ± 10 0.001 8 ± 10 8 ± 11 NS
SV (mL.m−2) 35 ± 8 39 ± 7 0.011 36 ± 8 39 ± 8 0.023
TPVR (mmHg.min.m2.L−1) 41 ± 16 38 ± 8 NS 42 ± 13 37 ± 7 0.014
TAC (mL.m−2.mmHg−1) 0.72 ± 0.22 0.75 ± 0.21 NS 0.69 ± 0.20 0.78 ± 0.211 0.021
Ea (mmHg.m2.mL−1) 2.9 ± 1.2 2.5 ± 0.6 0.044 2.8 ± 1.1 2.4 ± 0.6 0.009
Stroke work (L.mmHg.m−2) 3.1 ± 0.7 3.6 ± 0.9 0.006 3.4 ± 0.9 3.5 ± 0.8 NS
Changes in vascular parameters from baseline to 6 months
Diastolic BP (mmHg) −2 ± 17 −3 ± 14 NS −7 ± 14 0 ± 14 0.011
Mean BP (mmHg) 1 ± 21 −2 ± 15 NS −5 ± 17 2 ± 16 0.033
TPVR (mmHg.min.m2.L−1) −5 ± 17 −3 ± 8 NS −10 ± 12 1 ± 9 <0.0001
TAC (mL.m−2.mmHg−1) 0.1 ± 0.3 0.1 ± 0.2 NS 0.2 ± 0.2 0.0 ± 0.2 0.001
Ea (mmHg.m2.mL−1) −0.8 ± 1.2 −0.4 ± 0.6 0.032 −0.9 ± 0.9 −0.2 ± 0.6 <0.0001
NS non-significant; see Table 2 for the other abbreviations
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present analysis. Baseline characteristics are detailed in Ta-
bles 1 and 2. Mean age was 56 ± 10 years, 17% were
women, the MI-related vessel was the left anterior descend-
ing artery in 54% of cases and primary angioplasty was per-
formed on average 4.3 ± 2.3 h after the onset of chest pain.
At baseline CMR, mean LV ejection fraction (EF) was
42 ± 8%, 98% of patients exhibited an MI area with LGE
while 49% had microvascular obstruction.
Evolution at 6 months
Paired comparisons between baseline and 6 months are
detailed in Table 2. Most patients were still under beta-
blocker treatment (84%) at 6 months, as well as under
angiotensin enzyme converting (ACE) inhibitor (86%) al-
though only 52% of the overall population had an
equivalent dose corresponding to that targeted in post-
MI trials [18]. Only six patients received mineralocor-
ticoid receptor antagonist treatment and only two had
vasodilators other than ACE inhibitors.
On average, marked improvements were observed from
baseline to 6 months for all SV-derived parameters, including
TPVR, TAC and Ea, whereas BP levels remained unchanged.
An abnormally high TPVR (>40 mmHg.min.m2.L−1) was
documented in as many as 56 patients at baseline (46%) and
was still present in 27 (22%) at 6 months (p < 0.001). These
27 patients with a persistent high TPVR had a mean systolic
blood pressure of 144 ± 19 mmHg during the CMR exam,
with slightly over half (52%) under the level of 150 mmHg.
Most LV function parameters were also increased, on
average, namely EF, EDV, stroke volume, stroke work
and cardiac index (Table 2). Significant increases in EDV
only were documented in 21 patients (17%), in EF only
in 37 (31%), in both EDV and EF in 15 (12%) and in
neither EDV nor EF in 48 (40%).
Predictions of the increases in EDV and in EF
As detailed in Table 3, among baseline cardiac variables,
those reflecting MI severity (areas with LGE, micro-
vascular obstruction), were strongly correlated with a
6-month increase in EDV, whereas patients with an in-
crease in EF were rather characterized by a lower base-
line EF.
The 6-month increases in EDV and EF were addition-
ally predicted by a lower baseline SV (Table 3), and
among all SV-derived parameters, a lower baseline stroke
work was associated with an increase in EDV, whereas
worse functional vascular parameters at baseline (i.e.
higher Ea and TPVR and lower TAC) were associated with
an increase in EF. Finally, a 6-month improvement in
these vascular parameters was a main characteristic of
patients with an increase in EF (Table 3) with an espe-
cially notable decrease in TPVR between baseline and
6 months (in mmHg.min.m2.L−1: −10 ± 12 for patients
with EF-increase vs. +1 ± 9 for the others, p < 0.001).
The strongest multivariate correlates for the 6-month
increase in EF were the concomitant change in TPVR
(p < 0.001) and baseline EF (p = 0.028) (global R2 = 0.40),
while the strongest correlates for the 6-month increase in
EDV were baseline stroke work (p = 0.019) and presence
of microvascular obstruction at baseline (p = 0.001) (global
R2 = 0.21).
Figure 1 provides an illustration of the comparative
evolution of TPVR from baseline to 6 months between
the four groups of patients with increases in EDV only
(EDV+/EF-), EF only (EDV-/EF+), both EDV and EF
(EDV+/EF+) and neither EDV nor EF (EDV-/EF). Repre-
sentative cases are also shown in Fig. 2. The two main
observations are that i) the increase in EF was strongly
linked to a concomitant decline in TPVR (6-month
change in mmHg.min.m2.L−1, EDV-/EF-: +1 ± 8, EDV+/EF-:
+3 ± 9, EDV-/EF+: -7 ± 6, EDV+/EF+: -15 ± 20, p < 0.001)
and ii) the absence of EF improvement was associated
Fig. 1 Mean values (±SD) for baseline (black columns) and 6-month
(white columns) values of total peripheral vascular resistance (TPVR,
upper panel), for the mean difference in TPVR between baseline and
6 months (grey columns, median panel) and for the percentages of
patients with abnormally high TPVR (>40 mmHg.min.m2.L−1, lower panel)
in patients categorized in 4 groups: (i) those without any significant
increase in EF or EDV at 6 months (EF-/EDV-), (ii) those with an increase
in EF only (EF+/EDV-) or (iii) EDV only (adverse remodeling, EF-/EDV+),
and (iv) those with increase in both EF and EDV (EF+/EDV+). *: p< 0.05
for paired comparisons between baseline and 6 months
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with high persistent rates of abnormally high TPVR at
6 months (EDV-/EF-: 31%, EDV+/EF-: 38%, EDV-/EF+:
5%, EDV+/EF+: 13%, p = 0.007).
Lastly, of particular note, the 6–month increase in
EDV was mainly dependent on cardiac as opposed to
vascular parameters and particularly on the presence of
microvascular obstruction at baseline, as strengthened
by the following rates in the four groups: EDV-/EF-:
37%, EDV+/EF-: 76%, EDV-/EF+: 38%, EDV+/EF+: 73%
(p = 0.003).
Discussion
LV remodeling following acute MI was previously shown
to be difficult to predict at an individual level, although
a possible interfering role of the concomitant evolution
of vascular function has never been considered to
date. This remodeling may be regarded as an adaptive
mechanism for maintaining cardiac stroke volume after
the loss of contractile tissue [1]. Indeed, as schematically
represented in Fig. 3, stroke volume can be restored by an
increase in LV ejection fraction but also in end-diastolic
volume [1]. However, this increase in end-diastolic volume
is known to result in deleterious loading conditions, pro-
moting further enlargement and dysfunction, and thereby
resulting in an adverse vicious cycle [1].
In the present study, SV-derived parameters were se-
lected as independent predictors of LV remodeling. One
such parameter is the indexed stroke work which together
with the presence of microvascular obstruction provided
the strongest multivariate correlation with the 6-month
increase in end-diastolic volume. Indexed stroke work,
calculated by the product of mean BP and indexed SV,
provides an indication of the aortic flow that can poten-
tially be generated by the LV at sufficiently high pressure
and has been indubitably recognized as a strong prog-
nostic indicator in patients with severe MI and/or heart
failure [19, 20].
Microvascular obstruction, also known as “no reflow”,
is currently documented at short term after an acute MI,
attaining its maximal size after 48 h [4]. In accordance
Fig. 2 Mid-ventricular vertical long-axis slices at baseline and at 6 months obtained from late gadolinium enhancement (LGE) images (right panel)
and cine-MRI at end-diastole (ED, left panel) and end-systole (ES, middle panel), with LV parameters (EF for ejection fraction; EDV for end diastolic
volume and MVO for % of LV area with microvascular obstruction), in 3 representative cases of anterior infarction and 6-month increase(s): #1) in
EF only and a 6-month decrease in TPVR (-8 mmHg.min.m2.L-1), #2) in EDV only and no clear change in TPVR (-1 mmHg.min.m2.L-1) and #3) in
both EDV and EF and a 6-month decrease in TPVR (-11 mmHg.min.m2.L-1)
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with previous comparable studies, the present findings
show that microvascular obstruction was a strong pre-
dictor of a subsequent adverse remodeling (as defined by
an increase in LV volume [4, 21–23]), but not of the evo-
lution of LV ejection fraction [3]. The latter was rather
best predicted by systemic vascular resistance, another
SV-derived parameter reflecting LV afterload. More pre-
cisely, the 6-month change in TPVR was selected as the
strongest independent correlate of the concomitant en-
hancement in LV ejection fraction, together with the base-
line level of ejection fraction, with these two variables
accounting for up to 40% (corresponding to the R2 value)
of the significant increases in ejection fraction at 6 months.
By contrast, BP and its changes over time were not
found to be accurate indices of the evolution of LV after-
load in the months following acute MI. This point is
best illustrated by the observation that BP was, on aver-
age, unchanged between baseline and 6 months, whereas
all SV-derived parameters of arterial afterload were
markedly enhanced during this same period. These pa-
rameters included TPVR and TAC, which respectively
reflect the functions of distal and proximal arterial beds,
as well as Ea, which could be considered as representing
a more global index of vascular function [8–10].
Vascular function was likely markedly influenced in
the present instance by the medical regimen prescribed
after MI, especially by ACE inhibitors, which were pre-
scribed in approximately 85% of our patients throughout
the 6 months of follow-up. Other arterial vasodilators
were prescribed in only two patients and no patients
were on beta-blockers with vasodilating properties.
ACE inhibitors are known to favorably alter ischemic
LV remodeling with hemodynamic effects, including the
lowering of both TPVR and volume expansion, leading
to a reduction in LV wall stress, a main stimulus for ad-
verse remodeling [1, 24–26]. However, only half of our
patients received, at 6 months, the dose prescribed for
ACE inhibitors targeted in post-MI trials, in accordance
with results from previous observational studies [27].
SV values were also assessed with the SSFP sequence
and by subtracting end-systolic to end-diastolic LV vol-
umes. While these SSFP-SV values were in line with those
provided by the aortic phase-contrast sequence, they none-
theless differed slightly due to methodological consider-
ations (results not shown). Moreover, these SSFP-SV values
were not used in our analyses in order to avoid their inter-
dependence with the remodeling-related changes in LV
volumes which were assessed with the same LV contours.
Indeed, with the use of SSFP-SV values, any change and/or
error in the determination of LV contours would symmet-
rically affect both SV-derived and LV-remodeling variables,
leading to an exaggeration of the link between these two
groups of variables.
The present study furthermore shows that the decrease
in TPVR represents a key element for improving LV ejec-
tion fraction, as schematically illustrated in Fig. 3, whereas
LV ejection fraction remains a major prognostic indicator
after MI [28]. Therefore, it may firstly be hypothesized
that a decrease in TPVR might lead to enhance not only
LV ejection fraction but also the prognosis of certain cat-
egories of patients. Secondly, it is likely that such an im-
provement in TPVR could be targeted at least in patients
for whom TPVR was still abnormally high at 6 months.
These patients represented as many as 30% of those who
had no increase in EF and 38% of those with definite ad-
verse remodeling (i.e. those with a 6-month increase in
EDV but not in EF). Thirdly, it must be kept in mind that
while the presence of high TPVR constitutes a hallmark of
vascular disease, commonly leading to hypertension, a
clear rise in BP is frequently lacking in instances of cardiac
dysfunction [29]. Case in point, more than half of our pa-
tients with high TPVR still had normal or sub-normal sys-
tolic BP (< 150 mmHg) during the 6-month CMR exam.
Finally, it may be hypothesized that these high-TPVR
patients could benefit from a change in vasodilating drug
regimen with higher doses of ACE inhibitors and/or
other arterial vasodilator(s) even when BP is not clearly
elevated. Larger scale studies are obviously needed to deter-
mine the extent to which such a personalized therapeutic
strategy, based on the non-invasive CMR monitoring of
TPVR, could better orient LV remodeling toward its re-
verse form, as illustrated in Fig. 3. Nevertheless, this study
shows that functional vascular disease is frequent in the
background of acute MI, thereby limiting any further im-
provement in LV ejection fraction, and that this disease
Fig. 3 Schematic representation of the influence of the decrease in
systemic vascular resistance in the mechanisms leading to reverse
remodeling (where stroke volume (SV) may be improved owing to
an increase in ejection fraction (EF) with a decrease in end-systolic
volume (ESV)) but not to adverse remodeling (where SV improvement is
attributable to an increase in end-diastolic volume (EDV) in link with MI
severity and especially of microvascular obstruction). Note that adverse
and reverse remodeling correspond to different mechanisms and may
thus coexist in the same patients
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should be considered in a more global strategy of cardio-
vascular treatment and monitoring.
A certain degree of imprecision in SV measurement,
related to phase offset errors, remains the main limita-
tion for the use of phase contrast sequences, even when
these errors are tentatively corrected by ROI-based
methods [7]. Nevertheless, SV has been shown to be
successfully assessed with MRI phase-contrast sequences
with a lower than 10% error, an accuracy level unattain-
able by Doppler techniques [7]. Another limitation is the
absence of T2*- or T2-weighted imaging for quantifying
intramyocardial edema or intramyocardial hemorrhage,
whereas this could have led to further improvement in
the prediction of LV remodeling [4].
Conclusions
The present study shows that LV remodeling following
reperfused MI is linked to the concomitant evolution of
loading conditions and particularly to the variable decrease
in vascular resistance under standard care cardiovascular
medication. It is likely that the non-invasive CMR mon-
itoring of vascular resistance may help to tailor these
medications in order to improve vascular resistance
and consequently, LV ejection fraction.
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